TheCanakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) demonstratedreduction of cardiovascular events in patients with atherosclerosis with the useof neutralizing interleukin-1 beta (Il-1beta) [55]. This evidence concerns the gene IL1B and Venous thrombosis.